Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
When we were planning this issue, several friends and readers were a bit surprised. "A whole issue on OCD? Is there anything new to say about it?" There's plenty to say that's both new and old.
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.